TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy.
TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy.
复制标题
TNFRSF1B +676 T> G多态性预测接受化学放疗治疗的非小细胞肺癌患者的存活。
DOI：
10.1186/1471-2407-11-447
复制
发表时间：
2011-10-14
期刊：
影响因子：
3.8
通讯作者：
Wei Q
中科院分区：
文献类型：
--
作者：
Guan X;Liao Z;Ma H;Qian J;Liu Z;Yuan X;Gomez D;Komaki R;Wang LE;Wei Q
TNF-TNFR超家族中基因表达的失调已涉及包括非小细胞肺癌（NSCLC）在内的多种人类癌症。此外，改变基因表达的TNF-α和TNFRSF 1B基因的功能多态性可能与癌症的风险和临床结局相关。然而，很少有报道的研究调查了TNF-α和TNFRSF 1B的潜在功能SNP与放化疗治疗的NSCLC患者预后之间的关系。我们对TNF-α和TNFRSF 1B基因的5个潜在功能多态性进行了基因分型[TNF-α -308 G>A（rs 1800629）和-1031 T>C（rs1799964）; TNFRSF1B +676 T>G（rs1061622）、-1709 A>T（rs652625）和+1663 A>G（rs1061624）]。Kaplan-Meier生存分析、对数秩检验和考克斯比例风险模型用于评估这些变异与NSCLC总生存期（OS）之间的相关性。我们发现TNFRSF 1B +676 GG基因型与NSCLC的OS显著更好相关（GG vs. TT：校正HR = 0.38，95% CI = 0.15-0.94; GG vs. GT/TT：校正HR = 0.35，95% CI = 0.14-0.88）。进一步的多因素逐步考克斯回归分析显示TNFRSF 1B +676 GG是该NSCLC队列的独立预后预测因子（GG与GT/TT：HR = 0.35，95% CI = 0.14-0.85），存在淋巴结状态（N2-3 vs. N 0 -1：HR = 1.60，95% CI = 1.09-2.35）和肿瘤分期（T3-4 vs. T0-2：HR = 1.48，95% CI = 1.08-2.03）。虽然该SNP的确切生物学功能仍有待探索，但我们的研究结果表明TNFRSF 1B +676 T>G（rs 1061622）在NSCLC预后中可能发挥作用。需要进一步的大型和功能性研究来证实我们的发现。
The dysregulation of gene expression in the TNF-TNFR superfamily has been involved in various human cancers including non-small cell lung cancer (NSCLC). Furthermore, functional polymorphisms in TNF-α and TNFRSF1B genes that alter gene expression are likely to be associated with risk and clinical outcomes of cancers. However, few reported studies have investigated the association between potentially functional SNPs in both TNF-α and TNFRSF1B and prognosis of NSCLC patients treated with chemoradiotherapy. We genotyped five potentially functional polymorphisms of TNF-α and TNFRSF1B genes [TNF-α -308 G>A (rs1800629) and -1031 T>C (rs1799964); TNFRSF1B +676 T>G (rs1061622), -1709A>T(rs652625) and +1663A>G (rs1061624)] in 225 NSCLC patients treated with chemoradiotherapy or radiotherapy alone. Kaplan-Meier survival analysis, log-rank tests and Cox proportional hazard models were used to evaluate associations between these variants and NSCLC overall survival (OS). We found that the TNFRSF1B +676 GG genotype was associated with a significantly better OS of NSCLC (GG vs. TT: adjusted HR = 0.38, 95% CI = 0.15-0.94; GG vs. GT/TT: adjusted HR = 0.35, 95% CI = 0.14-0.88). Further stepwise multivariate Cox regression analysis showed that the TNFRSF1B +676 GG was an independent prognosis predictor in this NSCLC cohort (GG vs. GT/TT: HR = 0.35, 95% CI = 0.14-0.85), in the presence of node status (N2-3 vs. N0-1: HR = 1.60, 95% CI = 1.09-2.35) and tumor stage (T3-4 vs. T0-2: HR = 1.48, 95% CI = 1.08-2.03). Although the exact biological function for this SNP remains to be explored, our findings suggest a possible role of TNFRSF1B +676 T>G (rs1061622) in the prognosis of NSCLC. Further large and functional studies are needed to confirm our findings.
登录
查看更多内容
影响因子：
6.4
作者：
Matsuyama, Ryusei;Togo, Shinji;Shimada, Hiroshi
通讯作者：
Shimada, Hiroshi
影响因子：
5.3
作者：
Gaudet, Mia M.;Egan, Kathleen M.;Garcia-Closas, Montserrat
通讯作者：
Garcia-Closas, Montserrat
影响因子：
2.1
作者：
Jeong, P;Kim, EJ;Kim, WJ
通讯作者：
Kim, WJ
影响因子：
2.2
作者：
Das, S. N.;Baniasadi, V.;Kapuria, V.
通讯作者：
Kapuria, V.
影响因子：
29.4
作者：
Machado, JC;Figueiredo, C;Sobrinho-Simoes, M
通讯作者：
Sobrinho-Simoes, M